Radiotherapy for early stage diffuse large B-cell lymphoma with or without double or triple hit genetic alterations

References

• Dabaja BS, Advani R, Hodgson DC, et al. ACR appropriateness criteria® diffuse large b-cell lymphoma. Am J Clin Oncol. 2015;38:610–620.
   PubMed Web of Science ®Google Scholar
• Illidge T, Specht L, Yahalom J, et al. Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2014;89:49–58.
   PubMed Web of Science ®Google Scholar
• Campbell BA, Connors JM, Gascoyne RD, et al. Limited-stage diffuse large B-cell lymphoma treated with abbreviated systemic therapy and consolidation radiotherapy: involved-field versus involved-node radiotherapy. Cancer. 2012;118:4156–4165.
   PubMed Web of Science ®Google Scholar
• Persky DO, Miller TP. Localized large cell lymphoma: is there any need for radiation therapy? Curr Opin Oncol. 2009;21:401–406.
   PubMed Web of Science ®Google Scholar
• Wirth A. The rationale and role of radiation therapy in the treatment of patients with diffuse large B-cell lymphoma in the Rituximab era. Leuk Lymph. 2007;48:2121–2136.
   PubMed Web of Science ®Google Scholar
• Yahalom J. Radiation therapy after R-CHOP for diffuse large B-cell lymphoma: the gain remains. J Clin Oncol. 2010;28:4105–4107.
   PubMed Web of Science ®Google Scholar
• Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: southwest Oncology Group study 0014. JCO. 2008;26:2258–2263.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109:1857–1861.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Wright G, Tan B, Rosenwald A, et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA. 2003;100:9991–9996.
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright G, Dave SS, et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359:2313–2323.
   PubMed Web of Science ®Google Scholar
• Staiger AM, Ziepert M, Horn H, et al. Clinical impact of the cell-of-origin classification and the MYC/BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the german high-grade non-Hodgkin's lymphoma study group. J Clin Oncol. 2017;35:2515–2526.
   PubMed Web of Science ®Google Scholar
• Sehn LH, Gascoyne RD. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood. 2015;125:22–32.
   PubMed Web of Science ®Google Scholar
• Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28:3360–3365.
   PubMed Web of Science ®Google Scholar
• Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114:3533–3537.
   PubMed Web of Science ®Google Scholar
• Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood. 2011;117:2319–2331.
   PubMed Web of Science ®Google Scholar
• Abramson JS. The spectrum of double hit lymphomas. Hematol Oncol Clin North Am. 2016;30:1239–1249.
   PubMed Web of Science ®Google Scholar
• Copie-Bergman C, Cuilliere-Dartigues P, Baia M, et al. MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. Blood. 2015;126:2466–2474.
   PubMed Web of Science ®Google Scholar
• Li S, Seegmiller AC, Lin P, et al. B-cell lymphomas with concurrent MYC and BCL2 abnormalities other than translocations behave similarly to MYC/BCL2 double-hit lymphomas. Mod Pathol. 2015;28:208–217.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282.
   PubMed Web of Science ®Google Scholar
• Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. JCO. 2014;32:3048–3058.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. JCO. 2014;32:3059–3068.
   PubMed Web of Science ®Google Scholar
• German High-Grade Non-Hodgkin’s Lymphoma Study Group: rituximab and combination chemotherapy with or without radiation therapy in treating patients with B-cell non-Hodgkin’s lymphoma. <https://clinicaltrials.gov/show/NCT00278408>.
   Google Scholar
• Held G, Murawski N, Ziepert M, et al. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol. 2014;32:1112–1118.
   PubMed Web of Science ®Google Scholar
• Haque W, Dabaja B, Tann A, et al. Changes in treatment patterns and impact of radiotherapy for early stage diffuse large B cell lymphoma after Rituximab: a population-based analysis. Radiother Oncol. 2016;120:150–155.
   PubMed Web of Science ®Google Scholar
• Ng AK, Dabaja BS, Hoppe RT, et al. Re-examining the role of radiation therapy for diffuse large b-cell lymphoma in the modern era. J Clin Oncol. 2016;34:1443–1447.
   PubMed Web of Science ®Google Scholar
• Tumati V, Trivedi L, Li H-C, et al. Patterns of failure in patients with double hit or double expressor lymphomas: implications for radiation therapy. Int J Radiat Oncol Biol Phys. 2018;100:1126–1132.
   PubMed Web of Science ®Google Scholar
• Lamy T, Damaj G, Soubeyran P, et al. R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphoma. Blood. 2018;131:174–181.
   PubMed Web of Science ®Google Scholar
• Vargo JA, Gill BS, Balasubramani GK, et al. Treatment selection and survival outcomes in early-stage diffuse large b-cell lymphoma: do we still need consolidative radiotherapy?. JCO. 2015;33:3710–3717.
   PubMed Web of Science ®Google Scholar
• Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. JCO. 2012;30:3460–3467.
   PubMed Web of Science ®Google Scholar
• Wang XJ, Medeiros LJ, Bueso-Ramos CE, et al. P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphoma. Mod Pathol. 2017;30:194–203.
   PubMed Web of Science ®Google Scholar
• Staton AD, Cohen JB. A Clinician's approach to double-hit lymphoma: identification, evaluation, and management. J Oncol Pract. 2016;12:232–238.
   PubMed Web of Science ®Google Scholar
• Oki Y, Noorani M, Lin P, et al. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol. 2014;166:891–901.
   PubMed Web of Science ®Google Scholar
• Hu S, Xu-Monette ZY, Tzankov A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood. 2013;121:4021–4031. quiz 4250.
   PubMed Web of Science ®Google Scholar
• Landsburg DJ, Petrich AM, Abramson JS, et al. Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma. Cancer. 2016;122:559–564.
   PubMed Web of Science ®Google Scholar